INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 266 filers reported holding INTELLIA THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 0.75 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $1,371,133 | -21.5% | 61,266 | -3.5% | 0.01% | -16.7% |
| Q1 2024 | $1,746,747 | -6.4% | 63,495 | +3.8% | 0.01% | -14.3% |
| Q4 2023 | $1,865,805 | -17.7% | 61,194 | -14.6% | 0.01% | -26.3% |
| Q3 2023 | $2,266,522 | -35.9% | 71,680 | -17.3% | 0.02% | -32.1% |
| Q2 2023 | $3,533,261 | +14.5% | 86,642 | +4.7% | 0.03% | +7.7% |
| Q1 2023 | $3,084,763 | +2.1% | 82,768 | -4.5% | 0.03% | -3.7% |
| Q4 2022 | $3,022,695 | -24.6% | 86,635 | +20.9% | 0.03% | -27.0% |
| Q3 2022 | $4,010,000 | -2.7% | 71,658 | -10.0% | 0.04% | +12.1% |
| Q2 2022 | $4,122,000 | -25.7% | 79,639 | +4.4% | 0.03% | 0.0% |
| Q1 2022 | $5,546,000 | -34.3% | 76,319 | +6.8% | 0.03% | -25.0% |
| Q4 2021 | $8,447,000 | +10.7% | 71,442 | +25.6% | 0.04% | -4.3% |
| Q3 2021 | $7,630,000 | +54.5% | 56,879 | +86.5% | 0.05% | +58.6% |
| Q2 2021 | $4,937,000 | +97.7% | 30,491 | -2.0% | 0.03% | +81.2% |
| Q1 2021 | $2,497,000 | – | 31,108 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 744,160 | $54,078,000 | 5.79% |
| Discovery Value Fund | 986,173 | $71,665,000 | 5.28% |
| Ally Bridge Group (NY) LLC | 60,000 | $4,360,000 | 3.23% |
| MPM BioImpact LLC | 159,409 | $11,584,000 | 3.11% |
| ARK Investment Management | 8,981,029 | $652,651,000 | 2.72% |
| Elmwood Wealth Management, Inc. | 67,599 | $4,912,000 | 2.52% |
| Nikko Asset Management Americas, Inc. | 2,872,269 | $192,442,000 | 1.41% |
| Frazier Life Sciences Management, L.P. | 203,684 | $14,802,000 | 1.26% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 111,440 | $8,098,000 | 1.22% |
| Merlin Capital, Inc | 11,575 | $841,000 | 1.11% |